search
Back to results

Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells

Primary Purpose

Dry Age-related Macular Degeneration

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
retinal pigment epithelium transplantation
Sponsored by
Chinese Academy of Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Dry Age-related Macular Degeneration

Eligibility Criteria

55 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 55-80 years;
  • Clinical diagnosis is consistent with the definition of late dry AMD in the age-related eye disease study (AREDS) (with one or more >250 micron geographic atrophy in the fovea;
  • No CNV;
  • The BCVA of target eye will not be better than 20/200;
  • -8.00D<diopter<+8.00D,21mm<axis oculi≤28mm;
  • voluntary as test subjects, signed informed consent, regular follow-up on time.

Exclusion Criteria:

  • The macular atrophy caused by other diseases in addition to AMD;
  • Suffer from retinitis pigmentosa, choroidal retinitis, central serous chorositis, diabetic retinopathy or other retinal vascular and degenerative diseases besides AMD;
  • Lens opacities (affecting the central vision), glaucoma, uveitis, retinal detachment, optic neuropathy and other ocular history;
  • Other intraocular surgery history besides cataract surgery;
  • In the last 6 months, there were severe heart failure (New York Heart Association grade III and IV) or the left ventricular ejection fraction <35% in any examinations
  • One of the following circumstances: (1) dialysis or eGFR<20ml/min/1.73m2; (2) urinary protein / urinary creatinine is ≥1g/g; (3) creatinine or albumin / urinary creatinine is ≥600mg/g;
  • Chronic liver disease, ALT increased >3 times normal value of the upper limit;
  • Combined with other serious systemic diseases, such as cor pulmonale, severe COPD (FEV1%<50%) and so on;
  • Combined with severe infectious diseases (such as HIV, syphilis antibody positive, etc;
  • The quantitative detection of HCV-RNA was positive, the quantitative detection of HBV-DNA was greater than 103 IU/ml, and tuberculosis was in the contagious period, etc;
  • Patients who are using anticoagulant, or the platelet function is still not restored to normal after stopping antiplatelet drugs for 10 days(The results of VerifyNow test show that AUC is greater than 470 and PRU is more than 208);
  • Abnormal blood coagulation function or other obvious abnormal laboratory test results;
  • Malignant tumor and history of malignant tumor;
  • Women who are pregnant,prepare to be pregnant during the trial, be lactating;men who prepare to have baby during the trial;
  • Any immune deficiency;
  • Glucocorticoids or immunosuppressive drugs have been used in the last 3 months;
  • Antipsychotic drugs have been used in the last 3 months, such as antidepressants, antipsychotic drugs, and so on;
  • With hypersensitivity to tacrolimus or other macrolides;
  • The history of addiction to alcoholism or prohibited drugs;
  • Being participating in any intervention clinical trials;
  • Poor compliance, difficult to complete the study;
  • The person who did not receive the informed consent;
  • Some researchers believe that there may be situations that can increase risks of the subjects or interfere clinical trials (for example, patients are prone to mental stress, depression, mental disorders, cognitive dysfunction, etc.).

Sites / Locations

  • The first affiliated hospital of Zhengzhou universityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

retinal pigment epithelium transplantation

Arm Description

transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).

Outcomes

Primary Outcome Measures

safety and tolerance of transplantation
The safety and tolerance of transplantation of hESC-derived RPE will be considered safe: no above moderate adverse events or severe adverse events which related to transplantation of retinal pigment epithelial cells ; Cells without infectious; No tumorigenicity. Through the clinical signs of subjects and laboratory examination to judge the tolerance, integrity, repellency of RPE cells, and monitoring the presence of local or systemic infection, and presence of metastatic tumor cells.

Secondary Outcome Measures

Efficacy:Early treatment of diabetic retinopathy eye chart (ETDRs)
Visual function measure: change in visual acuity
Efficacy:Best corrected visual acuity(BCVA)
Visual function measure: change in visual acuity
Efficacy:Optical coherent tomography (OCT)
Visual function measure
Efficacy:fundus autofluorescence
Transplant and host retina integrity and survival
Efficacy:vision inspection
Changes of judgment after transplantation of patient's visual field

Full Information

First Posted
February 2, 2017
Last Updated
January 30, 2018
Sponsor
Chinese Academy of Sciences
Collaborators
The First Affiliated Hospital of Zhengzhou University
search

1. Study Identification

Unique Protocol Identification Number
NCT03046407
Brief Title
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells
Official Title
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Unknown status
Study Start Date
September 6, 2017 (Actual)
Primary Completion Date
January 2019 (Anticipated)
Study Completion Date
December 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese Academy of Sciences
Collaborators
The First Affiliated Hospital of Zhengzhou University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This project intends to transplant human embryonic stem cells derived retinal pigment epitheliums into subretinal space of patients to treat dry age-related macular degeneration(dry-AMD).And we will assess the safety and efficacy of RPE transplants to treat dry AMD.
Detailed Description
This project intends to transplant human embryonic stem cells derived retinal pigment epitheliums into subretinal space of patients to treat dry age-related macular degeneration(dry-AMD). Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the safety and efficacy of RPE transplants to treat dry AMD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Age-related Macular Degeneration

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
Open Label
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
retinal pigment epithelium transplantation
Arm Type
Experimental
Arm Description
transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
Intervention Type
Biological
Intervention Name(s)
retinal pigment epithelium transplantation
Intervention Description
Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
Primary Outcome Measure Information:
Title
safety and tolerance of transplantation
Description
The safety and tolerance of transplantation of hESC-derived RPE will be considered safe: no above moderate adverse events or severe adverse events which related to transplantation of retinal pigment epithelial cells ; Cells without infectious; No tumorigenicity. Through the clinical signs of subjects and laboratory examination to judge the tolerance, integrity, repellency of RPE cells, and monitoring the presence of local or systemic infection, and presence of metastatic tumor cells.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Efficacy:Early treatment of diabetic retinopathy eye chart (ETDRs)
Description
Visual function measure: change in visual acuity
Time Frame
12 months
Title
Efficacy:Best corrected visual acuity(BCVA)
Description
Visual function measure: change in visual acuity
Time Frame
12 months
Title
Efficacy:Optical coherent tomography (OCT)
Description
Visual function measure
Time Frame
12 months
Title
Efficacy:fundus autofluorescence
Description
Transplant and host retina integrity and survival
Time Frame
12 months
Title
Efficacy:vision inspection
Description
Changes of judgment after transplantation of patient's visual field
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 55-80 years; Clinical diagnosis is consistent with the definition of late dry AMD in the age-related eye disease study (AREDS) (with one or more >250 micron geographic atrophy in the fovea; No CNV; The BCVA of target eye will not be better than 20/200; -8.00D<diopter<+8.00D,21mm<axis oculi≤28mm; voluntary as test subjects, signed informed consent, regular follow-up on time. Exclusion Criteria: The macular atrophy caused by other diseases in addition to AMD; Suffer from retinitis pigmentosa, choroidal retinitis, central serous chorositis, diabetic retinopathy or other retinal vascular and degenerative diseases besides AMD; Lens opacities (affecting the central vision), glaucoma, uveitis, retinal detachment, optic neuropathy and other ocular history; Other intraocular surgery history besides cataract surgery; In the last 6 months, there were severe heart failure (New York Heart Association grade III and IV) or the left ventricular ejection fraction <35% in any examinations One of the following circumstances: (1) dialysis or eGFR<20ml/min/1.73m2; (2) urinary protein / urinary creatinine is ≥1g/g; (3) creatinine or albumin / urinary creatinine is ≥600mg/g; Chronic liver disease, ALT increased >3 times normal value of the upper limit; Combined with other serious systemic diseases, such as cor pulmonale, severe COPD (FEV1%<50%) and so on; Combined with severe infectious diseases (such as HIV, syphilis antibody positive, etc; The quantitative detection of HCV-RNA was positive, the quantitative detection of HBV-DNA was greater than 103 IU/ml, and tuberculosis was in the contagious period, etc; Patients who are using anticoagulant, or the platelet function is still not restored to normal after stopping antiplatelet drugs for 10 days(The results of VerifyNow test show that AUC is greater than 470 and PRU is more than 208); Abnormal blood coagulation function or other obvious abnormal laboratory test results; Malignant tumor and history of malignant tumor; Women who are pregnant,prepare to be pregnant during the trial, be lactating;men who prepare to have baby during the trial; Any immune deficiency; Glucocorticoids or immunosuppressive drugs have been used in the last 3 months; Antipsychotic drugs have been used in the last 3 months, such as antidepressants, antipsychotic drugs, and so on; With hypersensitivity to tacrolimus or other macrolides; The history of addiction to alcoholism or prohibited drugs; Being participating in any intervention clinical trials; Poor compliance, difficult to complete the study; The person who did not receive the informed consent; Some researchers believe that there may be situations that can increase risks of the subjects or interfere clinical trials (for example, patients are prone to mental stress, depression, mental disorders, cognitive dysfunction, etc.).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Wang Liu, Doctor
Phone
+86-01064807858
Email
wangliu@ioz.ac.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Hao Jie, Doctor
Phone
+86-01062558737
Email
haojie@ioz.ac.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhou Qi, Doctor
Organizational Affiliation
Institute of zoology, Chinese Academy of Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
The first affiliated hospital of Zhengzhou university
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450052
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wan guang ming, Doctor
Phone
0371-66862213
Email
wgm6608@163.com
First Name & Middle Initial & Last Name & Degree
Li fu zhen, Doctor
Phone
0371-66862213
Email
fuzhenlii@qq.com

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells

We'll reach out to this number within 24 hrs